IBS - Review and what's new

MedGenMed Medscape General Medicine

Volumn 8, Issue 3, 2006, Pages

  Foxx Orenstein, Amy ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALOSETRON; AMITRIPTYLINE; ANTIBIOTIC AGENT; BISACODYL; CASTOR OIL; CILANSETRON; CLONIDINE; DESIPRAMINE; DICYCLOVERINE; DOXEPIN; EMODIN; FLUOXETINE; HYOSCYAMINE; ISPAGULA; LOPERAMIDE; MAGNESIUM HYDROXIDE; PAROXETINE; PLACEBO; POLYCARBOPHIL CALCIUM; PREDNISOLONE; PROBIOTIC AGENT; RENZAPRIDE; SENNA EXTRACT; SEROTONIN; SEROTONIN RECEPTOR; SODIUM DIHYDROGEN PHOSPHATE; SORBITOL; TEGASEROD; TRIMIPRAMINE; UNINDEXED DRUG; GASTROINTESTINAL AGENT;

ABDOMINAL CRAMP; ABDOMINAL DISCOMFORT; ABDOMINAL PAIN; ANAMNESIS; BACTERIAL OVERGROWTH; BEHAVIOR THERAPY; BIFIDOBACTERIUM; BLOATING; CHRONIC DISEASE; CLINICAL TRIAL; COLITIS; CONSTIPATION; DIAGNOSTIC ACCURACY; DIAGNOSTIC PROCEDURE; DIARRHEA; DISEASE CLASSIFICATION; DISEASE SEVERITY; DIZZINESS; DRUG DOSE REGIMEN; DRUG MECHANISM; DRUG WITHDRAWAL; ECONOMIC ASPECT; ELECTROLYTE DISTURBANCE; ENVIRONMENTAL FACTOR; FATIGUE; GASTROINTESTINAL MOTILITY; GASTROINTESTINAL TRACT; GENETIC ANALYSIS; HEADACHE; HEALTH CARE SYSTEM; HUMAN; HYPOTENSION; HYPOVOLEMIA; INTESTINE INFECTION; IRRITABLE COLON; ISCHEMIC COLITIS; LABORATORY TEST; LACTOBACILLUS; MENTAL STRESS; NAUSEA; NERVOUSNESS; NUTRITIONAL INTOLERANCE; PATHOPHYSIOLOGY; PATIENT EDUCATION; PHYSICAL EXAMINATION; PREVALENCE; QUALITY OF LIFE; REVIEW; SIGNAL TRANSDUCTION; SOMNOLENCE; STREPTOCOCCUS; URINE RETENTION; XEROSTOMIA; BACTERIAL INFECTION; DISEASE PREDISPOSITION; ENVIRONMENT; GASTROENTEROLOGY; GENETICS; METABOLISM;

BACTERIAL INFECTIONS; DISEASE SUSCEPTIBILITY; ENVIRONMENT; GASTROENTEROLOGY; GASTROINTESTINAL AGENTS; HUMANS; IRRITABLE BOWEL SYNDROME; SEROTONIN; SIGNAL TRANSDUCTION;

EID: 33746887448     PISSN: 15310132     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (139)

1. American College of Gastroenterology Functional Gastrointestinal Disorders Task Force. Evidence-based position statement on the management of irritable bowel syndrome in North America. Am J Gastroenterol. 2002; 97:S1-S5.
2. Brandt LJ, Bjorkman D, Fennerty MB, et al. Systematic review on the management of irritable bowel syndrome in North America. Am J Gastroenterol. 2002; 97:S7-S26. Abstract
3. Drossman DA, Camilleri M, Mayer EA, Whitehead WE. AGA technical review on irritable bowel syndrome. Gastroenterology. 2002; 123:2108-2131. Abstract
4. Hungin APS, Tack J, Mearin F, Whorwell PJ, Dennis E, Barghout V. Irritable bowel syndrome (IBS): prevalence and impact in the USA - the truth in IBS (T-IBS) survey [abstract]. Am J Gastroenterol. 2002; 97:S280-S281.
5. Glia A, Lindberg G. Quality of life in patients with different types of functional constipation. Scand J Gastroenterol. 1997; 32:1083-1089. Abstract
6. Dean BB, Aguilar D, Barghout V, et al. Impairment in work productivity and health-related quality of life in patients with IBS. Am J Manag Care. 2005; 11:S17-S26. Abstract
7. Whitehead WE, Burnett CK, Cook EW III, Taub E. Impact of irritable bowel syndrome on quality of life. Dig Dis Sci. 1996;41:2248-2253. Abstract
8. El Serag HB, Olden K, Bjorkman D. Health-related quality of life among persons with irritable bowel syndrome: a systematic review. Aliment Pharmacol Ther. 2002;16:1171-1185. Abstract
9. Frank L, Kleinman L, Rentz A, Ciesla G, Kim JJ, Zacker C. Health-related quality of life associated with irritable bowel syndrome: comparison with other chronic diseases. Clin Ther. 2002;24:675-689. Abstract
10. Gralnek IM, Hays RD, Kilboume A, Naliboff B, Mayer EA. The impact of irritable bowel syndrome on health-related quality of life. Gastroenterology. 2000;119:654-660. Abstract
11. Martin R, Barron JJ, Zacker C. Irritable bowel syndrome: toward a cost-effective management approach. Am J Manag Care. 2001;7:S268-S275. Abstract
12. American Gastroenterological Association. The Burden of Gastrointestinal Diseases. Bethesda, MD: American Gastroenterological Association; 2001:1-86. Available at: http://www.gastro.org/clinicalRes/pdf/burden-report.pdf. Accessed November 16, 2004.
13. Camilleri M, Williams DE. Economic burden of irritable bowel syndrome. Proposed strategies to control expenditures. PharmacoEconomics. 2000;17:331-338. Abstract
14. Talley NJ, Gabriel SE, Harmsen WS, Zinsmeister AR, Evans RW. Medical costs in community subjects with irritable bowel syndrome. Gastroenterology. 1995;109:1736-1741. Abstract
15. Thompson WG, Longstreth GF, Drossman DA, Heaton KW, Irvine EJ, Muller-Lissner SA. Functional bowel disorders and functional abdominal pain. Gut. 1999;45(suppl II):1143-1147.
16. Manning AP, Thompson WG, Heaton KW, Morris AF. Towards positive diagnosis of the irritable bowel. BMJ. 1978;2:653-654. Abstract
17. Lembo TJ, Fink RN. Clinical assessment of irritable bowel syndrome. J Clin Gastroenterol. 2002;35:S31-S36. Abstract
18. Talley NJ, Phillips SF, Melton LJ, Mulvihill C, Wiltgen C, Zinsmeister AR. Diagnostic value of the Manning criteria in irritable bowel syndrome. Gut. 1990,31:77-81. Abstract
19. Thompson WG, Creed FH, Drossman DA. Functional bowel disorderand functional abdominal pain. Gastroenterol Int. 1992;5:75-91.
20. Drossman DA. The functional gastrointestinal disorders and the Rome III process. Gastroenterology. 2006;130:1377-1390. Abstract
21. Longstreth GF, Thompson G, Chey WD, et al. Functional bowel disorders. Gastroenterology 2006;130:1480-1491.
22. Whitehead WE, Palsson O, Levy R, et al. Agreement of rome criteria with clinical diagnosis of irritable bowel (IBS) [abstract]. Gastroenterology. 2003;124:A-397.
23. Vanner SJ, Depew WT, Paterson WG, et al. Predictive value of the Rome criteria for diagnosing the irritable bowel syndrome. Am J Gastroenterol. 1999;94:2912-2917. Abstract
24. Kwan AC-P, Bao TN, Chakkaphak S, et al. Validation of Rome II criteria for functional gastrointestinal disorders by factor analysis of symptoms in Asian patient sample. J Gastroenterol Hepatol. 2003;18:796-802. Abstract
25. Chey WD, Olden K, Carter E, Boyle J, Drossman D, Chang L. Utility of the Rome I and Rome II criteria for irritable bowel syndrome in U.S. women. Am J Gastroenterol. 2002;97:2803-2811. Abstract
26. Mearin F, Badia X, and the IBER Group. How restrictive are Rome II criteria for the diagnosis of irritable bowel syndrome (IBS) [abstract]? Gut. 2000;47:A215.
27. Thompson GW, Irvine JE, Pare P, Ferrazzi S, Rance L. Comparing Rome I and Rome II criteria for irritable bowel syndrome (IBS) in a prospective survey of the Canadian population [abstract]. Am J Gastroenterol. 2000;95:2553.
28. Williams RE, Black CL, Kim HY, et al. Stability of irritable bowel syndrome using a Rome II-based classification. Aliment Pharmacol Ther. 2006;23:197-205. Abstract
29. Zanten SV. Diagnosing irritable bowel syndrome. Rev Gastroenterol Dis. 2003;3:S12-S17.
30. Paterson WG, Thompson WG, Vanner SJ, et al. Recommendations for the management of irritable bowel syndrome in family practice. IBS Consensus Conference Participants. CMAJ. 1999; 161:154-160. Abstract
31. Camilleri M, Choi MG. Review article: irritable bowel syndrome. Aliment Pharmacol Ther. 1997;11:3-15.
32. Cash BD, Schoenfeld P, Chey WD. The utility of diagnostic tests in irritable bowel syndrome patients: a systematic review. Am J Gastroenterol. 2002;97:2812-2819. Abstract
33. Spiegel BM, Derosa VP, Gralnek IM, Wang V, Dulai GS. Testing for celiac sprue in irritable bowel syndrome with predominant diarrhea: A cost-effectiveness analysis. Gastroenterology. 2004; 126:1721-1732. Abstract
34. Hamm LR, Sorrells SC, Harding JP, et al. Additional investigations fail to alter the diagnosis of irritable bowel syndrome in subjects fulfilling the Rome criteria. Am J Gastroenterol. 1999;94:1279-1282. Abstract
35. Tolliver BA, Herrera JL, DiPalma JA. Evaluation of patients who meet clinical criteria for irritable bowel syndrome. Am J Gastroenterol. 1994;89:176-178. Abstract
36. Talley NJ. When to conduct testing in patients with suspected irritable bowel syndrome. Rev Gastroenterol Disord. 2003;3:S18-S24.
37. Adeniji OA, Barnett CB, Di Palma JA. Durability of the diagnosis of irritable bowel syndrome based on clinical criteria. Dig Dis Sci. 2004;49:572-574. Abstract
38. Locke GR, III. Natural history of irritable bowel syndrome and durability of the diagnosis. Rev Gastroenterol Dis. 2003;3:S12-S17.
39. Barbara G, De Giorgio R, Stanghellini V, Cremon C, Salvioli B, Corinaldesi R. New pathophysiological mechanisms in irritable bowel syndrome. Aliment Pharmacol Ther. 2004;20:1-9.
40. Drossman DA. What does the future hold for irritable bowel syndrome and the functional gastrointestinal disorders? J Clin Gastroenterol. 2005;39:S251-S256.
41. Engel GL. The need for a new medical model: a challenge for biomedicine. Science. 1977; 196:129-136. Abstract
42. Drossman DA. Gastrointestinal illness and the biopsychosocial model [editorial]. J Clin Gastroenterol. 1996;22:252-254. Abstract
43. Drossman DA. Presidential address: gastrointestinal illness and the biopsychosocial model. Psychosom Med. 1998;60:258-267. Abstract
44. Eutamene H, Theodorou V, Fioramonti J, Bueno L. Acute stress modulates the histamine content of mast cells in the gastrointestinal tract through interleukin-1 and corticotropin-releasing factor release in rats. J Physiol Lond. 2003;553:959-966. Abstract
45. Tache Y, Monnikes H, Bonaz B, Rivier J. Role of CRF in stress-related alterations of gastric and colonic motor function. Ann NY Acad Sci. 1993;697:233-243. Abstract
46. Sagami Y, Shimada Y, Tayama J, et al. Effect of a corticotropin releasing hormone receptor antagonist on colonic sensory and motor function in patients with irritable bowel syndrome. Gut. 2004;53:958-964. Abstract
47. Falk P. Is IBS a genetic disorder? FBG Newsletter. 2003:10-15.
48. Levy RL, Jones KR, Whitehead WE, Feld SI, Talley NJ, Corey LA. Irritable bowel syndrome in twins: heredity and social learning both contribute to etiology. Gastroenterology. 2001; 121:799-804. Abstract
49. Morris-Yates A, Talley NJ, Boyce PM, Nandurkar S, Andrews G. Evidence of a genetic contribution to functional bowel disorder. Am J Gastroenterol. 1998;93:1311-1317. Abstract
50. Locke GR, III, Zinsmeister AR, Talley NJ, Fett SL, Melton LJ III. Familial association in adults with functional gastrointestinal disorders. Mayo Clin Proc. 2000;75:907-912. Abstract
51. Camilleri M. Is there a SERT-ain association with IBS? Gut. 2004;53:1396-1399.
52. Barbara G, De Giorgio R, Stanghellini V, Cremon C, Corinaldesi R. A role for inflammation in irritable bowel syndrome? Gut. 2002;51 (suppl 1):141 -144.
53. Kim HJ, Camilleri M, Carlson PJ, et al. Association of distinct alpha(2) adrenoceptor and serotinin transporter polymorphisms with constipation and somatic symptoms in functional gastrointestinal disorders. Gut. 2004;53:829-837. Abstract
54. Holtmann G, Siffert W, Haag S, et al. G-protein beta3 subunit 825 CC genotype is associated with unexplained (functional) dyspepsia. Gastroenterology. 2004;126:971-979. Abstract
55. Mach T. The brain-gut axis in irritable bowel syndrome - clinical aspects. Med Sci Monit. 2004;10:RA125-RA131. Abstract
56. Spiller RC, Jenkins D, Thornley JP, et al. Increased rectal mucosal enteroendocrine cells, T lymphocytes, and increased gut permeability following acute Campylobacter enteritis and in post-dysenteric irritable bowel syndrome. Gut. 2000;47:804-811. Abstract
57. Dunlop SP, Jenkins D, Neal KR, Spiller RC. Relative importance of enterochromaffin cell hyperplasia, anxiety, and depression in postinfectious IBS. Gastroenterology. 2003;125:1651-1659. Abstract
58. Dunlop S, Jenkins D, Neal KR, et al. Randomized, double-blind, placebo-controlled trial of Prednisolone in post-infectious irritable bowel syndrome. Aliment Pharmacol Ther. 2003; 18:77-84. Abstract
59. Camilleri M. Mechanisms in IBS: something old, something new, something borrowed. Neurogastroenterol Motil. 2005;17:311-316. Abstract
60. O'Mahony L, McCarthy J, Kelly P, et al. Lactobacillus and bifidlobacterium in irritable bowel syndrome syndrome: symptom responses and relationship to cytokine profiles. Gastroenterology. 2005;128:541-551. Abstract
61. Harris LA, Chang L. Irritable bowel syndrome: new and emerging therapies. Curr Opin Gastroenterol. 2006;22:128-135. Abstract
62. Halpern GM, Prindiville T, Blankenburg M, let al. Treatment of irritable bowel syndrome with Lacteol Fort: a randomized, double-blind, cross-over trial. Am J Gastroenterol. 1996;91:1579-1585. Abstract
63. Kim HJ, Camilleri M, McKinzie S, et al. A randomized controlled trial of a probiotic: VSL#3, on gut transit and symptoms in diarrhea-predominant irritable bowel syndrome. Aliment Pharmacol Ther. 2003; 17:895-904. Abstract
64. Niv E, Naftali T, Hallak R, Vaisman N. The efficacy of Lactobacillus reuteri ATCC 55730 in the treatment of patients with irritable bowel syndrome: a double blind, placebo-controlled, randomized study. Clin Nutr. 2005;24:925.
65. Niedzielin K, Kordecki H, Birkenfield B. A controlled, double-blind, randomized study on the efficacy of Lactobacillus planetarum 299V in patients with irritable bowel syndrome. Eur J Gastroenterol Hepatol. 2001;13:1143-1147. Abstract
66. Noback S, Johansson ML, Molin G, et al. Alterations in intestinal microflora is associated with reduction in abdominal bloating and pain in patients with irritable bowel syndrome. Am J Gastroenterol. 2000;95:1231-1238. Abstract
67. O'Sullivan MA, O'Morain CA. Bacterial supplementation in the irritable bowel syndrome: a randomized doubleblind placebo-controiled cross-over study. Dig Liver Dis. 2000;32:294-301. Abstract
68. Sen S, Mullan MM, Parker TJ, et al. Effect of Lactobacillus plantarum 290v on colonic fermentation and symptoms of irritable bowel syndrome. Dig Dis Sci. 2002;47:2615-2620. Abstract
69. Quigley EM, Whorwell PJ, Altringer L, Morel J, O'Mahony L, Shanahan F. Who is the responder to probiotic therapy in IBS? Data from a controlled clinical trial with Bifidobacterium infantis 35624. Am J Gastroenterol. 2005; 100:S325-S326. [Abstract #887]
70. Lin Chang, MD. New updates in chronic constipation and irritable bowel syndrome. Medscape Gastroenterology. 2005. http://www.medscape.com/viewarticle/517739 Accessed May 25, 2006.
71. Pimentel M, Chow EJ, Lin HC. Eradication of small intestinal bacterial overgrowth reduces symptoms of irritable bowel syndrome. Am J Gastroenterol. 2000;95:3503-3506. Abstract
72. Pimentel M, Chow EJ, Lin HC. Normalization of lactulose breath testing correlates with symptom improvement in irritable bowel syndrome. A double-blind, randomized, placebo-controlled study. Am J Gastroenterol. 2003;98:412-419. Abstract
73. Parisi G, Leandro G, Bottona E, et al. Small intestinal bacterial overgrowth and irritable bowel syndrome. Am J Gastroenterol. 2003;98:2572-2574. Abstract
74. Riordan S, McIver C, Walker B, et al. The lactulose breath hydrogen test and small intestinal bacterial overgrowth. Am J Gastroenterol. 1996;9:1795-1803.
75. O'Leary C, Quigley EM. Small bowel bacterial overgrowth, celiac disease, and IBS: what are the real associations? Am J Gastroenterol. 2003;98:720-722.
76. Kerlin P, Wong L. Breath hydrogen testing in bacterial overgrowth of the small intestine. Gastroenterology. 1988;95:982-988. Abstract
77. Hamilton LH. Bacterial overgrowth. In: Breath Tests and Gastroenterology. 2nd ed. Milwaukee, Wis: Quintron Instruments; 1998.
78. Harris LA, Crowell MD, DiBaise JK, Olden K. Is small intestinal bacterial overgrowth (SIBO) really prevalent in irritable bowel syndrome (IBS)? Am J Gastroenterol. 2005; 100:S336-S337. [Abstract #920]
79. Pimentel M, Park S, Kong Y, et al. Rifaximin, a non-absorbable antibiotic, improves the symptoms of irritable bowel syndrome: a double-blind randomized controlled study. Am J Gastroenterol. 2005; 100:A-882.
80. Atkinson W, Sheldon TA, Shaath N, Whorwell PJ. Food elimination based on IgG antibodies in irritable bowel syndrome: a randomised controlled trial. Gut. 2004;53:1459-1464. Abstract
81. Gershon MD. The enteric nervous system: a second brain. Hosp Pract (Off Ed). 1999;34:31-32, 35-38, 41-42.
82. Crowell MD. The role of serotonin in the pathophysiology of irritable bowel syndrome. Am J Manag Care. 2001;7:S252-S260. Abstract.
83. Gershon MD. Serotonin and its implication for the management of irritable bowel syndrome. Rev Gastroenterol Disord. 2003;3:S25-S34.
84. Gershon MD. Nerves, reflexes, and the enteric nervous system: pathogenesis of the irritable bowel syndrome. J Clin Gastroenterol. 2005;39:S184-S193.
85. Fiorica-Howells E, Liu MT, Ponimaskin EG, et al. Distribution of 5HT4 receptors in wild-type mice and analyses of intestinal motility in 5 HT4 knockout mice. Presented at: Digestive Diseases Week and the 104th Annual Meeting of the American Gastroenterological Association; May 17-22, 2003; Orlando, Florida.
86. Chen JX, Pan H, Rothman TP, Wade PR, Gershon MD. Guinea pig 5-HT transporter: cloning, expression, distribution, and function in intestinal sensory reception. Am J Physiol. 1998;275:G433-G448. Abstract
87. Coates MD, Mahoney CR, Linden DR, et al. Molecular defects in mucosal serotonin content and decreased serotonin reuptake transporter in ulcerative colitis and irritable bowel syndrome. Gastroenterology. 2004; 126:1657-1664. Abstract
88. Miwa J, Echizen H, Matsueda K, Umeda N. Patients with constipation-predominant irritable bowel syndrome (IBS) may have elevated serotonin concentrations in colonic mucosa as compared with diarrhea-predominant patients and subjects with normal bowel habits. Digestion. 2001;63:188-194. Abstract
89. Bellini M, Rappelli L, Blandizzi C, et al. Platelet serotonin transporter in patients with diarrhea-predominant irritable bowel syndrome both before and after treatment with alosetron. Am J Gastroenterol. 2003;98:2705-2711. Abstract
90. Chen JJ, Li Z, Pan H, et al. Maintenance of serotonin in the intestinal mucosa and ganglia of mice that lack the high-affinity serotonin transporter: Abnormal intestinal motility and the expression of cation transporters. J Neurosci. 2001;21:6348-6361. Abstract
91. Yeo A, Boyd P, Lumsden S, et al. Association between a functional polymorphism in the serotonin transporter gene and diarrhoea predominant irritable bowel syndrome in women. Gut. 2004;53:1452-1458. Abstract
92. Camilleri M, Atanasova E, Carlson PJ, et al. Serotonin-transporter polymorphism pharmacogenetics in diarrhea-predominant irritable bowel syndrome. Gastroenterology. 2002;123:425-432. Abstract
93. Talley NJ. SSRIs in IBS: sensing a dash of disappointment. Clin Gastroenterol Hepatol. 2003;1:155-159. Abstract
94. Talley NJ. Antidepressants in IBS: are we deluding ourselves? Am J Gastroenterol. 2004;99:921-923.
95. Tries J, Plummer MK, Wisconsin OTR. Biofeedback and bowel disorders: Teaching yourself to live without the problem. Available at: http://www.aboutibs.org/Publications/Biofeedback.html Accessed May 26, 2006.
96. Irritable bowel syndrome. Available at: http://www.aapb.org/4a/pages/index.cfm?pageid=3368 Accessed May 26, 2006.
97. Lackner JM, Mesmer C, Morley S, Dowzer C, Hamilton S. Psychological treatments for irritable bowel syndrome: a systematic review and meta-analysis. J Consult Clin Psychol. 2004;72:1100-1113. Abstract
98. Camilleri M, Northcutt AR, Kong S, Dukes GE, McSorley D, Mangel AW. Efficacy and safety of alosetron in women with irritable bowel syndrome: a randomised, placebo-controlled trial. Lancet. 2000;355:1035-1040. Abstract
99. Jones RH, Holtmann G, Rodrigo L, et al. Alosetron relieves pain and improves bowel function compared with mebeverine in female nonconstipated irritable bowel syndrome patients. Aliment Pharmacol Ther. 1999;13:1419-1427. Abstract
100. Lembo T, Wright RA, Bagby B, et al. Alosetron controls bowel urgency and provides global symptom improvement in women with diarrhea-predominant irritable bowel syndrome. Am J Gastroenterol. 2001;96:2662-2670. Abstract
101. Lembo AJ, Olden KW, Ameen VZ, Gordon SL, Heath AT, Carter EG. Effect of alosetron on bowel urgency and global symptoms in women with severe, diarrhea-predominant irritable bowel syndrome: analysis of two controlled trials. Clin Gastroenterol Hepatol. 2004;2:675-682. Abstract
102. Lotronex[R] (alosetron hydrochloride) tablets [prescribing information]. Research Triangle Park, NC: GlaxoSmithKline; February 2005.
103. Chey WD, Chey WY, Heath AT, et al. Long-term efficacy and safety of alosetron in women with severe diarrhea-predominant irritable bowel syndrome. Am J Gastroenterol. 2004;99:2195-2203. Abstract
104. Chang L, Ameen VZ, Dukes GE, McSorley DJ, Carter EG, Mayer EA. A dose-ranging, phase II study of the efficacy and safety of alosetron in men with diarrhea-predominant IBS. Am J Gastroenterol. 2005;100:115-123. Abstract
105. Muller-Lissner SA, Fumagalli I, Bardhan KD, et al. Tegaserod, a 5-HT4 receptor partial agonist, relieves symptoms in irritable bowel syndrome patients with abdominal pain, bloating and constipation. Aliment Pharmacol Ther. 2001; 15:1655-1666. Abstract
106. Novick J, Miner P, Krause R, et al. A randomized, double-blind, placebo-controlled trial of tegaserod in female patients suffering from irritable bowel syndrome with constipation. Aliment Pharmacol Ther. 2002; 16:1877-1888. Abstract
107. Kellow J, Lee OY, Chang FY, et al. An Asia-Pacific, double blind, placebo controlled, randomised study to evaluate the efficacy, safety, and tolerability of tegaserod in patients with irritable bowel syndrome. Gut. 2003;52:671-676. Abstract
108. Nyhlin H, Bang C, Elsborg L, et al. A double-blind, placebo-controlled, randomized study to evaluate the efficacy, safety and tolerability of tegaserod in patients with irritable bowel syndrome. Scand J Gastroenterol. 2004;39:119-126. Abstract
109. Bardhan KD, Forbes A, Marsden CL, Mason T, Short G. The effects of withdrawing tegaserod treatment in comparison with continuous treatment in irritable bowel syndrome patients with abdominal pain/discomfort, bloating and constipation: a clinical study. Aliment Pharmacol Ther. 2004;20:213-222. Abstract
110. Muller-Lissner S, Holtmann G, Rueegg P, Weidinger G, Loffler H. Tegaserod is effective in the initial and retreatment of irritable bowel syndrome with constipation. Aliment Pharmacol Ther. 2005;21:11-20.
111. Zelnorm [R] (tegaserod maleate) tablets (prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; August 2004.
112. Tougas G, Snape WJ Jr, Otten MH, et al. Long-term safety of tegaserod in patients with constipation-predominant irritable bowel syndrome. Aliment Pharmacol Ther. 2002; 16:1701-1708. Abstract
113. Coremans G, Clouse RE, Carter F, Krause G, Caras S, Steinborn C. Cilansetron, a novel 5-HT3 antagonist, demonstrated efficacy in males with irritable bowel syndrome with diarrhea-predominance (IBS-D) [abstract]. Gastroenterology. 2004;126(suppl 2):A643.
114. Cilansetron: KC 9946. Drugs Res Dev. 2005;6:169-173.
115. Bradette M, Moennikes H, Carter F, Krause G, Caras S, Steinborn C. Cilansetron in irritable bowel syndrome with diarrhea predominance (IBS-D): efficacy and safety in a 6 month global study [abstract]. Gastroenterology. 2004;126:A42.
116. Clouse RE, Caras S, Cataldi F, Carter F, Krause G, Steinborn C. Cilansetron is efficacious for relief of urgency in patients with irritable bowel syndrome with diarrhea predominance (IBS-D). Program and abstracts of the First European Society for Pediatric Gastroenterology and Nutrition (ESPGHAN) Capri meeting; May 27-29, 2004; Naples, Italy.
117. Galligan JJ, Vanner S. Basic and clinical pharmacology of new motility promoting agents. Neurogastroenterol Motil. 2005; 17:643-653. Abstract
118. Cremonini F, Talley NJ. Treatments targeting putative mechanisms in irritable bowel syndrome. Nat Clin Pract Gastroenterol Hepatol. 2005;2:82-88. Abstract
119. Meyers NL, Palmer RMJ, George A. Efficacy and safety of renzapride in patients with constipation-predominant IBS: a phase llb study in the UK primary healthcare setting [abstract]. Gastroenterology. 2004;126:A640.
120. Henderson JC, Palmer RMJ, Meyers INL, Spiller RC. A phase llb clinical study of renzapride in mixed-symptom (alternating) irritable bowel syndrome [abstract]. Gastroenterology. 2004; 126:A644.
121. Camilleri M, Kim D-Y, McKinzie S, et al. A randomized, controlled exploratory study of clonidine in diarrhea-predominant irritable bowel syndrome. Clinical gastroenterology and Hepatology. 2003;1:111-121. Abstract
122. Delgado-Aros S, Chiall HJ, Camilleri M, et al. Effects of a kappa-opioid agonist, asimadoline, on satiation and GI motor and sensory functions in humans. Am J Physiol Gastrointestinal Liver Physiol. 2003;284:G558-G566.
123. Camilleri M. Treating irritable bowel syndrome: overview, perspective and future therapies. Br J Pharmacol. 2004; 141:1237-1248. Abstract
124. Su X, Julia V, Gebhart GF. Effects of intracolonic opioid receptor agonists on polymodal pelvic nerve afferent fibers in the rat. J Neurophysiol. 2000;83:963-970. Abstract
125. Ozaki N, Sengupta JN, Gebhart GF. Differential effects of mu-, delta and kappa-opioid receptor agonists on the mechanosensitive gastric vagal afferent fibers in the rat. J Neurophysiol. 2000;83:2209-2216. Abstract
126. Delvaux M, Beck A, Jacob J, et al. Effect of asimadoline, a kappa opioid agonist, on pain induced by colonic distension in patients with irritable bowel syndrome. Aliment Pharmacol Ther. 2004;20:237-246. Abstract
127. Lubiprostone: RU 0211, SPI 0211. Drugs Res Dev. 2005;6:245-248.
128. Orr KK. Lubiprostone: a novel chloride channel activator for the treatment of constipation. Formulary. 2006;41:118-120, 122, 128-129.
129. Horvath EJ, Horvath K, Hamori T, et al. Anxiolytic 2,3, benzodiazepines, their specific binding to the basal ganglia. Prog Neurobiol. 2000;60:309-342. Abstract
130. Horvath EJ, Horvath K, Hamori T, Fekete MI, Solyom S, Palkovits M. Anxiolytic 2,3-benzodiazepines, their specific binding to the basal ganglia. Prog Neurobiol. 2000;60:309-342. Abstract
131. Leventer S, Raudibaugh K, Mangel A, et al. Dextofisopann improves bowel function in men and women with IBS. Am J Gastroenterol. 2005;100:S344. [Abstract #941]
132. Leventer S, Raudibaugh K, Frissora C, et al. The safety and efficacy of dextofisopam in patients with diarrhea-predominant or alternating irritable bowel syndrome. Gastroenterology. 2005; 128:A94.
133. Pres release: Vela announces positive phase 2 results for dextofisopam in treating irritable bowel syndrome-IBS; results show effects of dextofisopam both in women and in men. Business Wire; January 6, 2005. Available at: http://www.centerwatch.com/bookstore/nmt/nmtb_ibs.pdf Accessed May 25,2006.
134. Currie MG, Kurtz C, Mahajan-Miklos S, Busby RW, Fretzen A, Geis S. Effects of single dose administration of MD-1100 on safety, tolerability, exposure, and stool consistency in healthy subjects. Am J Gastroenterol. 2005; 100: S328. [Abstract #894]
135. Press release: Microbia successfully completes phase IA trial of MD-1100 for IBS-C and other Gl disorders. Microbia, Inc; May 17, 2005. Available at: http://www.prnewswire.com/cgi-bin/stories.pi? ACCT=104&STORY=/www/ story/ 05-17-2005/0003633751&EDATE= Accessed May 25, 2006.
136. Phase 2 study of MD-1100 acetate on gastrointestinal transit in patients with C-IBS. Available at: http://www.clinicaltrials.gov/ct/show/NCT00258193?order=7 Accessed May 26, 2006.
137. Xing JH, Soffer EE. Adverse effects of laxatives. Dis Colon Rectum. 2001;44:1201-1209. Abstract
138. Trindade E, Menon D, Topfer LA, Coloma C. Adverse effects associated with selective serotonin reuptake inhibitors and tricyclic antidepressants: a meta-analysis. CMAJ. 1998; 159:1245-1252. Abstract
139. Camilleri M, Kim D-Y, McKinzie S, et al. A randomized, controlled exploratory study of clonidine in diarrhea-predominant irritable bowel syndrome. Clin Gastroenterol Hepatol. 2003;1:111-121. Abstract